Please wait while we load the requested 10-Q report or click the link below:
Fifty-three subjects have now been enrolled at sites in the United States and Europe in VTL-308, the Company’s phase 3 randomized, controlled, open-label trial, designed to evaluate the ELAD System in subjects with severe acute alcoholic hepatitis (sAAH). There are now 40 sites open for enrollment in VTL-308. The enrollment rate has accelerated over the past 3 months to about 9 subjects per month and the Company continues to expect to report topline data around mid-2018.
The Company entered into a collaboration with Drexel University in Philadelphia and the University of Birmingham in the UK, two of the key clinical sites that participated in VTI-208 and are also VTL-308 clinical sites. The collaboration is exploring the potential for ELAD to resuscitate marginal donor livers and thereby increase the supply of livers available for transplantation.
An oral presentation entitled "Early Change in Bilirubin Level (ECBL) as a Surrogate for Outcome in ELAD Clinical Study of Severe Alcoholic Hepatitis (sAH)" was made at the Asian Pacific Association for the Study of the Liver (APASL) meeting in Shanghai, China, on February 19, 2017. The presenter was Dr. Tarek Hassanein, a physician investigator in the VTI-208 and VTL-308 clinical trials from the Southern California Research Center, Coronado, CA, United States. The presentation can be found on the Company’s Investor Relations web site under the "Clinical Publications and Presentations" section.
The following information was filed by Vital Therapies Inc (VTL) on Tuesday, March 7, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Vital Therapies Inc's financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Vital Therapies Inc.